These companies could innovate their way to success.

Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...

To our immune system, a potentially lifesaving gene therapy can look a lot like a dangerous infection. That's because most ...

Global CRISPR Technology Market OverviewThe global CRISPR technology market is poised for strong expansion, projected to grow at a robust CAGR of approximately 16% over the next five years. This ...

Revolutions in gene therapy are rapidly changing the landscape of modern medicine, forcing society and science alike to ...

To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

Urnov is a professor of molecular therapeutics at the University of California, Berkeley, and a director at its Innovative Genomics Institute. In May, news broke of a biomedical first: the on-demand ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...